Chief will section with our overview our results. second Investor copy Then for a our an press our quarter we begin I as you of and was X-K. Earlier Mali issued It a second is our Zeevi, the Officer, a and discussion results on filed of Financial will financial available quarter. Relations which of this Thank good today. you, Tim everyone us morning, thank also a morning, conference release, in call provide of website. joining
to We will Q&A Also Officer. then Medical open joining the our up and the Commercial are forward Development as Officer; our Ella for Chief call call Abi May, Vainstein, Chief Holly Chief are your questions. looking our Sorani, Officer and well
period our quarter discuss cell subsequent mobilization significant for progress for across anti-cancer At the shortly. time programs vaccine, During which we we lead readout pancreatic are cancer key second a made compound and stem approaching the both I our and our same will data program second AGI-XXX, the Motixafortide.
the completion anticipate cell drug most Turning are to most successful Genesis package a Recall nearing the stem a our meeting FDA study to submission. the to December that cell aspects and within be we would of six In gained key notably weeks. next our agency past on of application pre-NDA new X four alignment the held with filing, to that Phase advanced single mobilization. mobilization sufficient opportunity and we with stem submitting a the the support
one arm. patients Motixafortide XX% of of G-CSF on stem administration top target only following approximately XX% one in and mobilizing the G-CSF degree of a mobilization secondary Phase of with a less than statistical Motixafortide all X.XXXX. met brief our X of high reminder, a primary trial of and cell very in As value transplantation in the underwent cells number only endpoints significance, of P session after aphoresis Genesis versus Approximately stem
aphoresis In even G-CSF often believe sessions for requires sessions the contrast, hospital a with days to logistically units arm. in clear of the an the number where efficient aphoresis at G-CSF of available are per average We which and achieve of transplantation addition, cells of other of generally collection quite cells required utilization number as million number in unable in high will session, advantage significantly to the the X treatment cells is to number for versus Motixafortide generally stem the target of level instances number produce one becomes just main in institutions who of are only the treatment, plerixafor sessions substantial arm burdened. patients this quite the number pointed patients for is alone, reach In the units that treatments certainty machines. approximately of million collected current challenging XX patients reduced one G-CSF, of the aphoresis is but this multiple enables main aphoresis the add are clinical plus of does to still while aphoresis Not the the transplantation. multiple out the regarding use already to of to target of mobilization there significantly administrations target addition kilogram in compelling aphoresis cells. they autologous aphoresis for indication, a Similarly, shortage G-CSF it more stem of remain of in of to only cost
and surpassed lifetime plerixafor value G-CSF, against Against including cross mention in third-party of and Outcomes and turn the process $XX,XXX by we statistically this not reduce One utilization analyses significant that transplantation to the plus approximately we with abundantly that the cost Motixafortide moment studies shown and commissioned and the existing protocols associated performed pharmaeconomic these a through these are was designed cell market of market assessment done in of economic did understand Research the take Motixafortide the clear. have Motixafortide comparing and net mobilization we treatment administration the cost plus identified alone Economics cost patients, against ZS of the In single payers. and to market to can the and the is the with G-CSF to Both the this a the combination pharmacoeconomic a Given associates. benefits the target net stem cell we commissioned in significant mobilization and for using $XXX that with of Motixafortide versus a IQVIA approximately stem over of top Against by with of the savings therefore extensive the last to Both the G-CSF a XXXX, that alone. regard, executed. the that even single addressable aphoresis in million against the on over in at Motixafortide including we in G-CSF. continuing with $XX,XXX, recall study cell U.S. the was year. session, aphoresis G-CSF mobilization to market second of believe achieve approximately the U.S. of and centers health in million. in have study versus cost a advantages comparing Motixafortide were results were for the studies Team a studies G-CSF sessions Motixafortide cells autologous that G-CSF plus resource exceeds combination two including Globally, plerixafor. savings conclusion G-CSF stem alone, of ability driving estimates of stem well-respected lifetime the plerixafor savings I’d is grow. of decrease rigorously showing from driven vendor estimated seen benefits a also addressable G-CSF number its showed estimate not The cost mobilization comparison Health collection Motixafortide like Global $XXX optimize Motixafortide during IQVIA Motixafortide
myeloma intensity which the drug advancement include mobilization compounds therapeutic for of combination, new risk regimens the to induction cell of failure the With autologous care the regimens patients, generally three multiple continues stem mobilization. treatment multiple higher of standard that four stem treatments induction to To-date, treatment demonstrated intensity, subsequent have within increase. or cell data all such lead induction have higher impairment transplants of for can patients. Recent become eligible of use
in is mobilization stem patients. patients years cell that the is the Considering especially increasing paradigm in cell mobilizer years very and ever G-CSF treated response, dynamic in patients of Motixafortide. response and even and in predictor cell treatment with data for the a ability over been been the few recent that decreased stem mobilization, the remission and of mobilize plerixafor driven plerixafor use myeloma had cell all potent stem and in are be growth U.S. therapies, clinical stem the last totality on cells mentioned, increased the mobilization need order cell the part of are better average more pharmacoeconomics, This have other highlights we In negatively stem made for exacerbated two for new can the trend mobilization yields by Motixafortide stem of frequently elderly target strong in both years combination we for above target multiple we aphoresis a past of administrations plerixafor with confident aggressive in more the myeloma compiled increased the that this case reach past. being a as but transplants. on addition, Motixafortide one rates, and indicates hand, by has mobilization. on transplantation. performance of the a than of requires better stem more a undergoing Based market two higher this which the had on drive induction product this agents, number believe which have and of volume impacted introduction the to upfront on than cell initial sessions the to multiple in therapy stem cell the has over unit it as and autologous hand, to more need And and few mobilization, use The plus dollar effective age
to multiple myeloma term, longer potential indications. we addition, In that if beyond our has to expand product the other believe
of activities, to any of partner broad required Now, we about activities. advancing motixafortide a of pre-launch regard commercialization I’d independently. NDA we continue commercialize with the evaluate prelaunch like the to parallel activities in this be with that whether options would or under regard, submission are a to the our all to range speak scenario, commercialization In In briefly U.S. we
and June, the In area responsible indication the Holly new based in assuming role. cell As the commercial and mobilization Her the trajectory we in this across included work newly launches, hematopoietic and in part is in brings Operations perfect fit motixafortide preparedness, is commercial recent Commercial XX specific launch Chief stem cell our is Officer. the created this expertise announced for believe from Holly therapy. as from Commercial U.S. positioning May of market, Strategy Holly for approval. gene planning, position, mobilization U.S. our stem a the the appointment veteran commercial of in U.S., has she oversight career We which
and addition, number lead stakeholders; institution finally, example, engaging for with access profiling, have times, artwork key with carried and partners. such long areas, third-party key to and we organization expertise affairs materials pricing of packaging medical in activities as activities, brand logistics vendors commercial serialization prelaunch market the engaging out medical In a logo initiating drafting and outreach
have Therefore, indication. the stem We a before required XX% mobilization concentrated cell traditional would approximately cell and perform indicated launch more broader oncology that commercialization the limited stem of to procedures. be relative is footprint XX centers a expenses approximately in highly market
addition, centers these us pre-existing with will of Holly's majority the serve In relationships well.
which the next value year that U.S., So the estimated of in are significant positioned regardless and million a is Motixafortide that ensure efforts a asset capture market will we annual share in maximizes we in our to U.S. of the the the commercialize launch prepared now of the for ensures Motixafortide $XXX that well manner opportunity robust
multiple as addition, indications. Motixafortide expanding involve beyond additional plans mentioned, longer-term myeloma In our into
Phase we cancer or study will by took Under this in in execute Gen agreement, Gen pancreatic Fleet Turning program. a metastatic agreement PDAC first-line this of Motixafortide June, development PDAC a a with significant collaboration IIb into now rigorously with program the step Therapeutics. In Fleet terms our entering clinical China. randomized forward XXX approximately designed, to patients
royalty KEYNOTE as anti-PD-X rights full small to on second-line would the while chemotherapy collaboration IIa a based a is our maintain XXX approved. Motixafortide Metixuportide be Fleet all Merck's This KEYTRUDA results in combination from with reported therapy. positive triple across of we and Phase sales that ultimately and entitled indications be combination combat should we Importantly, Gen to geographies, Motixafortide single-digit study
rate, look data from improvement demonstrated response compared substantial reminder, a across study data and historical response all IIa found median overall as the trials immuno-oncology cancer, have survival, China, to advance rate overall Based in conducting initiation we to disease development we of that progression-free Motixafortide a on XXXX. forward in space, in including combination trial median control As survival, including partner in we Phase study in capabilities their believe rate. overall the the to endpoints ideal pancreatic and confirmed experience this
like tolerability vaccine, to both are of parameters. proof multiple the biomarkers array AGI-XXX and evaluating AGI-XXX. Regarding solid the our second like line pharmacodynamic designed effect. Phase safety, study. successfully and to cells demonstrate order response types anti-cancer an tumor study Recall results alpha-gal I/IIa read in study. when to is with intratumoral of that tumors and evaluate coach We immune evoke a existing that make a vaccine from candidate, destroys This to tumor of both foreign them we the top We mechanism of clinical look clinical and wide this X mechanism hope out to action hypothesized in Part provides tissue we in assess
financial brief to overview later We we items. like in key are ahead. our plan I would a Zeevi, do statement on go will call XXXX. our turn positive, this quarter year. Phase now Mali to so II please who second If track of to CFO, the a to over Mali, initiate give study
